Trowbridge Stephen A sold $311K of ANGO
Trowbridge Stephen A (EVP and CFO) sold 25,335 shares of ANGIODYNAMICS INC (ANGO) at an average of $12.26 ($12.17–$12.27, $0.31M total) across 2 trades over 2026-10-28 to 2026-10-29.
How this was made
The 30-second read
Why it matters
The CFO's sale reduces his ownership and may be interpreted as a negative signal, but the modest size limits market reaction.
Market read
A routine insider sale with limited material impact; investors may monitor for further insider activity.
What to watch
No 10b5‑1 plan was used, suggesting the sale was discretionary.
Background
SEC Form 4 filing discloses insider transactions. Such filings are primary sources for insider activity.
Ticker impact
CFO Stephen Trowbridge sold 25,335 shares for $310,688, reducing his stake to 280,461 shares.
likely pressure as the market prices in the insider selling
The sale amount is modest ($311K) but involves a senior executive, which can prompt short‑term selling by investors.
Market effects
Minimal impact on the medical device sector; the sale is company‑specific.
No broader regional effect.
Limited to Angiodynamics shareholders.
Counterpoint
The sale could be unrelated to confidence and merely a personal liquidity event, so price impact may be negligible.
Key entities
- OfficerStephen A. Trowbridge
Executive Vice President and Chief Financial Officer of Angiodynamics.
